12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Recomodulin: Phase III started

Asahi Kasei began a double-blind, placebo-controlled, international Phase III trial to evaluate 0.06 mg/kg IV ART-123 for up to 6 mg per day for 6 days in...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >